Rslcan-1 Inhibitors
Chemical inhibitors of Rslcan-1 encompass a range of compounds that can impede the activity of this protein by targeting various signaling pathways and enzymatic activities associated with it. Staurosporine, a broad-spectrum kinase inhibitor, can inhibit Rslcan-1 by obstructing the protein's kinase activity, which is crucial for its function. Similarly, genistein and lestaurtinib, both tyrosine kinase inhibitors, can inhibit Rslcan-1 if it possesses tyrosine kinase activity or is regulated by tyrosine kinases. Bisindolylmaleimide I, a specific inhibitor of protein kinase C (PKC), can also inhibit Rslcan-1 if there is a regulatory relationship or interaction with PKC. Wortmannin and LY294002, inhibitors of phosphoinositide 3-kinases (PI3K), can suppress the PI3K/AKT pathway, which potentially involves Rslcan-1 in its downstream signaling cascade, leading to a decrease in Rslcan-1's activity.
In addition to these kinase-targeting agents, several inhibitors act on the mitogen-activated protein kinase (MAPK) pathway components, which may interact with or affect Rslcan-1 function. SP600125, an inhibitor of JNK, can reduce the activity of Rslcan-1 if it is a part of or influenced by the JNK signaling pathway. SB203580 and U0126, which inhibit p38 MAP kinase and MEK1/2 respectively, can also attenuate Rslcan-1 activity by blocking upstream signaling events that lead to Rslcan-1 activation. PD98059, another MEK inhibitor, likewise can have an impact on Rslcan-1 by preventing the activation of downstream kinases such as ERK, which may be necessary for Rslcan-1's activity. Lastly, rapamycin inhibits mTOR, a central protein in the PI3K/AKT pathway, which can suppress Rslcan-1 activity if its function is linked to this particular signaling route. Each of these chemical inhibitors can act on different components of the cellular signaling pathways, which in turn modulate the activity of Rslcan-1, demonstrating the interconnected nature of cellular signaling and the multiple points at which Rslcan-1's activity can be influenced.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor known to inhibit a wide range of protein kinases. Since Rslcan-1 has kinase activity, staurosporine can inhibit Rslcan-1 by preventing its catalytic activity, thereby directly inhibiting the protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is involved in many signaling pathways. By inhibiting PI3K, LY294002 can diminish the downstream signaling that may include the activity of Rslcan-1, thus functionally inhibiting the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. Rslcan-1, being a part of cellular signaling, may rely on JNK activity. By inhibiting JNK, SP600125 can reduce Rslcan-1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. If Rslcan-1 activity is downstream of p38 MAPK signaling, SB203580's inhibition of p38 MAPK can lead to a reduction in Rslcan-1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which operates upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can indirectly inhibit Rslcan-1 if Rslcan-1's function is downstream of ERK activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases. By inhibiting this kinase, wortmannin can suppress the PI3K/AKT pathway, which could be upstream of Rslcan-1 function, thus leading to the inhibition of Rslcan-1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key protein in the PI3K/AKT pathway. By inhibiting mTOR, rapamycin can suppress the downstream effects that could include the action of Rslcan-1, thereby inhibiting the protein functionally. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Rslcan-1, if associated with cellular processes involving Src kinases, would be functionally inhibited by the action of PP2 on these kinases. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK1/2, U0126 can block the activation of ERK and thus indirectly inhibit the function of Rslcan-1. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. Rslcan-1, if it has tyrosine kinase activity or is regulated by tyrosine kinases, would be functionally inhibited by genistein's inhibitory action on these kinases. | ||||||